A review article discussing current and emerging therapies for chronic cutaneous GVHD, including extracorporeal photopheresis, and second-line drugs targeting T cells, B cells, and inflammatory cytokines. The authors discuss the growing knowledge of the pathogenesis of cutaneous GVHD, focusing on the role of B cells and the utility of rituximab therapy. The authors also introduce a clinical algorithm to guide clinicians in treating limited and extensive cutaneous GVHD, as well as steroid refractory or persistent cutaneous GVHD where steroid sparing is indicated.
Emerging Therapies for Chronic Cutaneous GVHD
Apr 2013